About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, September 5th, 2012

The QualityStocks
Daily Stock List


Omni Bio Pharmaceutical, Inc. (OMBP)

SmallCapVoice and SeriousTraders reported earlier on Omni Bio Pharmaceutical, Inc. (OMBP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Omni Bio Pharmaceutical, Inc. is a biopharmaceutical company that lists on the OTCQB. The Company initially formed to explore new methods of use of an FDA-approved drug, Alpha 1-antitrypsin (AAT) also referred to as "plasma-derived AAT." AAT is purified from human blood and is widely believed to be the body's most powerful anti-inflammatory protein. Omni Bio Pharmaceutical is based in Greenwood Village, Colorado.

The AAT drug has a greater than 20-year safety record as an approved treatment for emphysema in AAT-deficient patients. Omni Bio Pharmaceutical’s initial strategy was based on licensing "methods of use" patents and patent applications that cover new indications for AAT and commercializing these via royalty agreements with existing AAT manufacturers. The Company’s initial markets were infectious diseases, including biohazards.

However, in 2009, Omni Bio Pharmaceutical changed their focus to auto-immune and inflammatory diseases such as Type 1 diabetes (juvenile diabetes). The Company is the licensee of patents and patent applications related to methods of use for plasma-derived AAT. At present, they hold three licenses with RUC in the areas of treatments for diabetes, graft rejection/cellular transplantation, bacterial disorders, and viral disorders.

They additionally hold a fourth license to an issued patent for the treatment of diabetes with a privately-held company, Bio Holding, Inc. To date, Omni Bio Pharmaceutical’s business efforts have been primarily dedicated to pursuing additional capital to fund SRAs related to evaluating the therapeutic effects of plasma-derived AAT on bacterial disorders, viral disorders and diabetes, and developing several synthetic fusion proteins involving Fc-AAT, and funding a human clinical trial using plasma-derived AAT to evaluate their therapeutic effects in the treatment of Type 1 diabetics.

Omni Bio Pharmaceutical is currently in negotiations with RUC and Konkuk University in South Korea for an exclusive license to patent applications covering Fc-AAT. In the second half of 2011, the Company started to look at novel alternatives to create Fc-AAT and filed provisional patent applications for compositions, methods and uses for Fc-AAT. Currently, Omni Bio Pharmaceutical is evaluating a variety of forms of Fc-AAT. The Company indicates that they will likely select one for further development.

Omni Bio Pharmaceutical, Inc. (OMBP), closed on Tuesday at $0.3950, up 19.70%, on 200 volume with 1 trade. The average volume for the last 60 days is 6,766 and the stock's 52-week low/high is $0.30/$3.88.

Aastrom Biosciences, Inc. (ASTM)

Street Insider, TheStockAdvisor, MicroCap Gems, DrStockPick, CRWEWallStreet, BestOtc, PennyOmega, PennyToBuck, StockHotTips, CRWEPicks, CRWEFinance, and PennyTrader Publisher reported earlier on Aastrom Biosciences, Inc. (ASTM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Aastrom Biosciences, Inc. is a regenerative medicine company developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe, chronic cardiovascular diseases. The Company’s commitment is to the development of stem cell treatments for critical cardiovascular diseases. Aastrom is currently evaluating their autologous cellular therapies in late-stage U.S. clinical trials. Founded in 1989, Aastrom Biosciences has their headquarters in Ann Arbor, Michigan.

The Company's proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced ixmyelocel-T into late-stage clinical development. This includes a Phase 3 clinical program to study patients with critical limb ischemia (CLI) and a planned Phase 2b clinical trial in patients with ischemic dilated cardiomyopathy (DCM).

Ixmyelocel-T is a patient-specific, expanded multicellular therapy, manufactured using the Company’s proprietary, highly automated, fully closed cell-processing system. Aastrom Biosciences’ patent-protected technology selectively expands mesenchymal cells, monocytes and alternatively activated macrophages, up to several hundred times more than the number found in the patient’s bone marrow. This is while retaining many of the hematopoietic cells collected from only a small sample (50ml) of the patient’s bone marrow.

Today, Aastrom Biosciences announced the appointment of Mr. Daniel (Dan) R. Orlando as Chief Commercial Officer. This is a newly created position at the Company. Most recently, Mr. Orlando was with Takeda Pharmaceuticals for more than 13 years in executive leadership positions in marketing, sales and business development, most recently as Vice President, Business Development for North and South America. Previously, he was with Abbott Laboratories for more than 11 years in progressive sales and marketing roles. During his career, he has helped to establish dozens of pharmaceutical brands including, most significantly, Actos®. Under his leadership, Actos® became the top brand in diabetes.

Recently, Aastrom Biosciences reported operating results for the quarter and six months ended June 30, 2012. They reported a net loss attributable to common shareholders for the quarter and six months ended June 30, 2012 of $8.6 million, or $0.22 per share, and $18.3 million, or $0.47 per share, respectively. This is in comparison to $10.0 million, or $0.26 per share, and $14.9 million, or $0.39 per share, for the same periods a year prior. The change in net loss compared to the quarter and six months ended June 30, 2011 is mainly due to the non-cash change in the fair value of warrants, offset by increases in research and development expenses.

Aastrom Biosciences, Inc. (ASTM), closed on Tuesday at $1.70, up 1.19%, on 199,749 volume with 497 trades. The average volume for the last 60 days is 253,389 and the stock's 52-week low/high is $1.52/$2.91.

Enova Systems, Inc. (ENA)

AfterMarketNews, DrStockPick, PennyOmega, CRWEWallStreet, StockHotTips, CRWEFinance, CRWEPicks, BestOtc, and PennyToBuck reported earlier on Enova Systems, Inc. (ENA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Founded in 1976, Enova Systems, Inc. is an innovator of Electric Vehicle (EV) and Hybrid Electric Vehicle (HEV) solutions. The Company believes it is a leader in the development, design, and production of proprietary, power train systems and related components for electric and hybrid electric buses and medium and heavy duty commercial vehicles. Their focus is on developing clean technologies for commercial vehicles. Enova Systems is based in Torrance, California.

A basic element of the Company’s strategy is to develop and produce advanced proprietary software and hardware for applications in these alternative power markets. Their corporate focus is power train systems (including digital power conversion, power management, and system integration) focusing primarily on vehicle power generation. In particular, Enova Systems develops, designs, and produces drive systems and related components for electric, hybrid electric, and fuel cell powered vehicles in the new and retrofit markets. The Company also performs internal research and development (R&D) as well as funded third party R&D to supplement their product development and to support their customers.

Enova’s product development strategy is to design and introduce to market successively advanced products, each based on their core technical competencies. In each of the Company’s product/market segments, they provide products and services to take advantage of their core competencies in digital power management, power conversion and system integration. Enova Systems chief market focus centers on aligning the Company with key customers and integrating with original equipment manufacturers (OEMs) in their target markets.

This past May, Enova Systems announced that they completed the shipment of 50 hybrid drive systems to First Auto Works (FAW) to date in 2012. This fulfilled the order of 50 systems announced in January of 2012. Additionally, it confirmed an incremental order for hybrid drive system components in excess of $200,000 for delivery in Quarter 2 and Quarter 3, 2012. FAW is one of The People’s Republic of China’s largest vehicle producers, manufacturing greater than 1,000,000 vehicles each year. Enova Systems and FAW have deployed, since 2008, close to 550 vehicles, all utilizing Enova’s pre-transmission hybrid drive system components.

Enova Systems, Inc. (ENA), closed on Tuesday at $0.0750, down 16.67%, on 529,235 volume with 422 trades. The average volume for the last 60 days is 337,648 and the stock's 52-week low/high is $0.032/$0.666.

ERBA Diagnostics, Inc. (ERB)

Stock Twiter, Secret Stock Club, StocksGoneWild, EpicVIP Group, Epic Stock Picks, SmallCapVoice, Bull in Advantage, and Penny Stock Rumble reported earlier on ERBA Diagnostics, Inc. (ERB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

ERBA Diagnostics, Inc. is a fully integrated in vitro diagnostics company. ERBA develops, manufactures and distributes, in the U.S. and around the world, proprietary diagnostic reagents, test kits, and instrumentation, mainly for autoimmune and infectious diseases, by way of their three subsidiaries. These subsidiaries are Diamedix Corp. (U.S.), Delta Biologicals S.r.l. (Europe), and ImmunoVision, Inc. (U.S.).

ERBA Diagnostics has their corporate headquarters in Miami, Florida. The Company formerly went by the name IVAX Diagnostics, Inc. They changed their name to ERBA Diagnostics, Inc. in June of this year. The Company’s shares trade on the NYSE market.

Their Diamedix subsidiary develops and manufactures in vitro diagnostics kits. They market these in conjunction with their MAGO® Plus instruments for use in clinical and hospital laboratories. The ImmunoVision subsidiary develops manufactures and markets autoimmune reagents and research products for use in clinical laboratories, research laboratories, as well as other diagnostic manufacturing companies.

The Delta Biologicals subsidiary develops scientific instrumentation, manufactures the MAGO® Plus instrument, and distributes in vitro diagnostic products. These are to public hospitals and private medical laboratories in Italy and other global markets.

Recently, ERBA Diagnostics reported their financial results for the quarter ended June 30, 2012. Net revenues for the second quarter of 2012 were $4,315,000 compared with $4,375,000 in the second quarter of 2011. This represents a decrease of $60,000, or 1.4 percent. Net revenue in the six months ended June 30, 2012 increased by $75,000, or 1 percent, from the same period last year.

Gross profit for the second quarter of 2012 was $2,204,000, or 51.1 percent of net revenue. This is in comparison to $2,360,000 or 53.9 percent of net revenue for the second quarter of 2011. Gross profit for the six months ended June 30, 2012 decreased by $148,000, or 3.3 percent, from the same period in the prior year.

Net loss for the second quarter of 2012 was $359,000, or $0.01 loss per share, compared with a net loss of $767,000, or $0.02 loss per share, in the second quarter of 2011. Net loss for the six months ended June 30, 2012 was $437,000, or $0.01 loss per share. This is compared to a net loss of $1,788,000, or $0.05 loss per share, in the same period of 2011.

ERBA Diagnostics, Inc. (ERB), closed on Tuesday at $0.45, down 8.16%, on 10,190 volume with 43 trades. The average volume for the last 60 days is 4,879 and the stock's 52-week low/high is $0.29/$0.80.

Organic Plant Health, Inc. (OPHI)

OtcWizard, MajorPennyStocks, Stock Twiter, Stock Runway, Investor News Source, Penny Dreamers, and Orbit Stocks reported earlier on Organic Plant Health, Inc. (OPHI), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Organic Plant Health, Inc. provides organic-based, natural and environmentally responsible fertilizers, soil conditioners, herbicides, insecticides and fungicides for the continual care of residential and commercial landscapes. Key customers using the Company’s products include environmentally conscious do-it-yourself homeowners and commercial landscape companies. Secondary markets served include real estate development companies, vineyards and agriculture. Organic Plant Health lists on the OTCQB. Founded in 2007, the Company is based in Indian Trail, North Carolina.

Organic Plant Health offers liquid and granular organic and natural fertilizers, weed controls, insect and disease controls, and soil amendments and conditioners for the turf care, shrub and ornamental tree care, and vegetable garden and flower beds markets. In addition, the Company offers specific formulations for vegetable and flower gardens. Organic Plant Health brand products presently sell in an assortment of independent retail locations across North and South Carolina. These include hardware stores, garden centers and plant nurseries.   

Today, Organic Plant Health released an end of summer progress report. They reported that their Q2 revenue is up approximately 4 percent over 2011; their Q2 operating expenses are down. Furthermore, the Company is in active discussions with a U.S. TV Media/Marketing company regarding national marketing and distribution of the new Eco-Cedar INDOOR Insect and Bed Bug control product. The Company expects to receive a Letter of Intent (LOI) very soon.

Additionally, the realization of the Corpotool distribution agreement is progressing well for Organic Plant Health. This will provide the Company access to more than 9,000 new stores through Corpotool's existing distribution. Company President and CEO, Mr. Billy Styles, traveled to Florida recently to work with the Corpotool sales and management team on training and sales calls to potential retailers to gauge initial interest. Each of the stores visited expressed interest and a desire to sell Organic Plant Health products at their location.

Moreover, Organic Plant Health is focusing their immediate geographic retail expansion into the Coastal Carolina region, central Georgia and southern Florida. The Company’s intention is to increase name recognition in areas where they have an existing presence. Their intention is also to build company and brand awareness in areas targeted for expansion.

Organic Plant Health, Inc. (OPHI), closed on Tuesday at $0.0650, down 18.75%, on 200,914 volume with 27 trades. The average volume for the last 60 days is 45,089 and the stock's 52-week low/high is $0.05/$0.1998.

Caspian Services, Inc. (CSSV)

OTCPicks reported earlier on Caspian Services, Inc. (CSSV), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTC Bulletin Board, Caspian Services, Inc. provides various oilfield services for the oil and gas industry in western Kazakhstan and the Kazakhstan sector of the Caspian Sea. The Company’s services fall into three categories. These are Marine Services, Marine Infrastructure Services, and Geophysical Services. Established in 1999, Caspian Services has their headquarters in Almaty, Republic of Kazakhstan.

The Company offers a growing slate of services to oil and gas exploration companies operating on land. Caspian Services has recognition as an industry leader in Kazakhstan’s offshore marine services industry. At present, the Company’s primary focus is on the developing offshore oil industry and its related infrastructure requirements. The Company is also focusing on the provision of marine and land based seismic services.

Caspian Services provides offshore marine services through Caspian Services Group Ltd. Seismic acquisition services are provided by Caspian Geophysics Ltd. and their two subsidiary companies, Tat Arka LLP and Kazmorgeophysica with infrastructure development assets being owned and operated by Caspian Real Estate Ltd.

Concerning Marine Services, Caspian Services is a leader in the industry in the Republic of Kazakhstan. The Company has a fleet of 15 shallow draft vessels ranging from accommodation and work barges capable of entering waters as shallow as 1.7 meters to marine seismic source vessels capable of working in waters 2 meters deep.

As pertains to Marine Infrastructure, Caspian Services, via their subsidiary Caspian Real Estate, is actively developing infrastructure projects that facilitate development of the oil and gas sector in Kazakhstan. These activities presently focus on the port of Bautino. This port is the most northern naturally ice free port on the Kazakh coastline in the winter; it is a natural staging point for support works during the summer. Balykshi LLP, a subsidiary of Caspian Real Estate, is currently constructing a marine base in the port of Bautino, to offer support services to vessels working the waters of the Kazakh sector of the Caspian Sea.

For Geophysics Services, the Company, through their subsidiary Caspian Geophysics, provides onshore, transition zone and marine seismic data acquisition services. They provide these services to the national oil company and independent oil and gas exploration and development companies operating in Kazakhstan and the Caspian Sea.

Caspian Services, Inc. (CSSV), closed on Tuesday at $0.0280, up 3.70%, on 3,740 volume with 1 trade. The The average volume for the last 60 days is 19,913 and the stock's 52-week low/high is $0.015/$0.11.

NaturalNano, Inc. (NNAN)

Investor News Source, CrushTheStreet.com, Penny Dreamers, Fast Moving Stocks, and Penny Stock Rumble reported yesterday on NaturalNano, Inc. (NNAN); All In Stocks, VIP Penny Stocks, Stocktwiter did last week, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Rochester, New York, NaturalNano, Inc. is a materials science company concentrating on developing and commercializing advanced nanocomposites. The Company is focusing on additive technologies and processes. This includes their proprietary Pleximer that adds value to industrial polymers, plastics and composites. In early May 2012, NaturalNano announced that the US Patent & Trademark Office (USPTO) granted the Company a patent application covering the use of their proprietary Halloysite NanoTubes (HNT) as a key strengthening component to enhance the performance of Polymeric Composite materials including Nano-particle Fillers.

NaturalNano holds and/or licenses 20 patents and applications relating to Halloysite, as well as proprietary expertise for their extraction and separation processes, compositions, and derivatives. The Company is developing proprietary technologies and processes to provide novel properties for an extensive array of applications. These applications include industrial polymers, plastics and composites; and additives to cosmetics, agricultural, and household products. 

Pleximer™ is a turnkey concentrate in the form of pellets. It can be added directly into the extruder by the end manufacturer. Pleximer contains Halloysite clay nanotubes, which are blended with a specific polymer base utilizing NaturalNano's patent pending technology. The resulting product is a drop-in additive. Halloysite nanotubes are ultra-tiny hollow tubes with diameters typically smaller than 100 nanometers (100 billionths of a meter), with lengths generally ranging from approximately 500 nanometers to more than 1.2 microns (millionths of a meter). 

In July, NaturalNano announced that the USPTO issued to the Company a patent covering the use of the Company’s proprietary Halloysite NanoTubes (HNT) in polymeric composite materials including Nano-particle Fillers as a key strengthening component to enhance their performance. The Company continues to expand and protect the commercial applications for their HNT additives. In this patent, the USPTO recognized the use of HNT additives as an important component of materials used to improve mechanical properties in materials for electrical shielding and may also may be used to augment the performance of eluting agents.

NaturalNano, Inc. (NNAN), closed on Tuesday at $0.003, down 9.09%, on 858,159 volume with 22 trades. The average volume for the last 60 days is 415,065 and the stock's 52-week low/high is $0.002/$0.20.

Armistice Resources Corp. (AZ.TO)

Stockhouse reported previously on Armistice Resources Corp. (AZ.TO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Armistice Resources Corp. is an exploration and development company that lists on the Toronto Stock Exchange and the OTC Pink Current Information (AISCF). In April 2012, the Company started shipping and milling ore from their McGarry Mine. The McGarry Mine is in Virginiatown on the prolific Larder Lake-Cadillac Break that extends 200 km east-west straddling the Ontario and Quebec border. Incorporated in 1984, Armistice Resources has their headquarters in Kirkland Lake, Ontario.

The Company is advancing two core projects. Along with the aforementioned McGarry Mine, their projects include the Kerr-Addison Mine. Refining and sales of the gold concentrate resulting from the milling at the McGarry Mine began last month. The McGarry Mine consists of 33 contiguous patented mining claims, including three licenses of occupation, totaling 484 hectares. The McGarry Mine is fully permitted; all equipment and systems at the site have been brought up to standards, including its installed mining plant. The McGarry Mine is adjacent to the Kerr-Addison Gold Mine.

Armistice Resources has signed a definitive five-year option agreement for the purchase of up to 100 percent of the mineral rights on the Kerr-Addison property. This property hosts an historical resource and is presently in advanced exploration. It has approximately 11 million oz Au of historical production. Both of the Company’s projects are located in the heart of Canada’s gold mining district. Some of the underground workings from the Kerr-Addison Mine extend directly onto the McGarry Mine property.

Yesterday, Armistice Resources announced that they commenced shipments and sales of gold concentrate from their McGarry gold mine in Ontario's Kirkland Lake area. The initial shipment of concentrate to a smelter marks their first generation of revenue and operating cash flow. The McGarry Mine is now approaching production of 200 tons of ore daily. The Company is targeting ramp-up to a rate of 350-400 tons daily by 2013.

The initial concentrate production was from lower-grade ore mined during the pre-production phase. The Company is now extracting higher-grade ore for shipment to the mill. Approximately 3,500 tons of broken ore are currently stockpiled for shipment to the mill. Armistice Resources is experiencing strong results from ongoing definition drilling in the McGarry Mine. Approximately three-quarters of the 80 definition holes drilled in the current stoping areas encountered visible gold. A number of assays returned in excess of one ounce per ton.

Armistice Resources Corp. (AZ.TO), closed on Tuesday at $0.1650, down 2.94%, on 42,100 volume. The stock's 52-week low/high is $0.13/$0.38.


The QualityStocks
Company Corner


GlobalWise Investments, Inc. (GWIV)

The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $1.01, up 26.25%, on 2,550 volume with 5 trades. The stock’s average daily volume over the past 60 days is 5,418, and its 52-week low/high is $0.61/$1.87.

GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.

GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.

The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.

GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer

GlobalWise Investments Company Blog

GlobalWise Investments News:

GlobalWise Announces New Channel Sales Partnership With RJ Young

GlobalWise Accepted as Member of Prestigious Organization Technology United

GlobalWise CEO to Be Featured Speaker at World Expo 2012 Conference

Loans4Less.com, Inc. (LFLS)

The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.04, even for the day. The stock’s average daily volume over the past 60 days is 23,311, and its 52-week low/high is $0.01/$0.51.

Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.

Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.

The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.

Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulting on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer

Loans4Less.com, Inc. Company Blog

Loans4Less.com, Inc. News:

Loans4Less.com, Inc. Announces Engagement of QualityStocks Investor Relations Services.

MusclePharm Corp. (MSLP)

The QualityStocks Daily Newsletter would like to spotlight MusclePharm Corp. (MSLP). Today, MusclePharm Corp. closed trading at $0.0113, down 1.74%, on 3,967,322 volume with 45 trades. The stock’s average daily volume over the past 60 days is 1,326,279, and its 52-week low/high is $0.0055/$0.0375.

MusclePharm Corp. (MSLP) is focused on providing a full line of Informed Choice-approved nutritional supplements that not use any substances banned in the sports industry. Now sold in more than 120 countries and available in over 10,000 U.S. retail outlets, the company's products address all categories of an active lifestyle, including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen.

Current CEO Brad Pyatt founded the company to develop a superior line of nutritional supplements that would help fellow athletes improve their performance in a way that existing supplements did not. Even as the company has grown, its mission has remained the same: to improve its customers' lives, increase their ability to excel, use cutting-edge science to develop the best nutritional supplements on the market, and provide a safe option for athletes.

MusclePharm's products were developed through exhaustive research at the MusclePharm Sports Science Center Research Institute. New products are created through a six-stage research protocol that involves the expertise of top nutritional scientists. Before launching a product, the company conducts field testing using a pool of over one hundred elite professional athletes from various professional sports leagues, including the National Football League, Mixed Martial Arts, and Major League Baseball.

Over the last few years, the consumption of sports nutrition products has shifted to mainstream consumers who have become the key drivers of growth within the industry. Teenagers and college students, women, and even older individuals are now using these products to help them live a more active and healthier lifestyle. With a full line of supplements and an extensive distribution network, MusclePharm is well positioned to capitalize on the growing demand. Disclaimer

MusclePharm Corp. Company Blog

MusclePharm Corp. News:

United States Sports Academy Researchers Present Clinical Trial Results For MusclePharms' Assault™ Pre-Workout

MusclePharm Announces Board Changes, Expansion

MusclePharm Nominated For 18 Bodybuilding.com Supplement Awards

Duma Energy Corp. (DUMA)

The QualityStocks Daily Newsletter would like to spotlight Duma Energy Corp. (DUMA). Today, Duma Energy Corp. closed trading at $1.35, down 4.93%, on 3,032 volume with 7 trades. The stock’s average daily volume over the past 60 days is 7,382, and its 52-week low/high is $1.10/$4.00.

Duma Energy Corp. (DUMA) is an aggressive growth company actively producing oil and gas in the domestic United States, both on and offshore. Leveraging its technical expertise, promising portfolio, and strong financial condition, the company plans to utilize domestic revenues and cash flow to fund its rapid growth through acquisition, while participating in transformational projects with the potential of providing exponential returns for shareholders.

The company's primary goal for fiscal year 2012 and beyond is to drive earnings growth. The company also aims to pursue listing on major exchange(s) to provide better visibility and liquidity to shareholders and financial partners. Already producing and generating revenue from oil and gas in Texas, Illinois, and Louisiana, Duma projects domestic production to exceed 1,000 barrels of oil equivalent per day (boepd) by the end of 2012; with 2,500 boepd projected by the end of 2013.

Duma was founded in 2005 and began trading on the OTCBB in 2009 via registration. In 2006, the company began producing from its first properties in Texas and soon after added production in Louisiana. In 2009, its new CEO Jeremy G. Driver came on board. Within one year, Mr. Driver had identified and negotiated an acquisition that would fundamentally reshape the company. This acquisition was made possible by the large direct cash investment by Mr. Driver and his family, as well as other investors.

The company uses only industry standard and time-tested technologies, and avoids unproven "resource plays" and other opportunities that are heavily dependent upon high commodity prices. Not bound by any geographical location or operational strategy, Duma's management team is focused on developing its existing portfolio while pursuing additional opportunities that provide rapid growth, leveraging growing revenue, cash flow, and reserves to accelerate its growth strategy. Disclaimer

Duma Energy Corp. Company Blog

Duma Energy Corp. News:

Duma Energy Acquires Interest in 5.3 Million-Acre African Concession

Duma Energy Enters Final Stage of Negotiations for African Concession

Duma Energy Provides Third Quarter Results and Demonstrates Positive Earnings

Duma Energy Corp. (DUMA) Uses Current Production to Support Exploration for Future Development

When Duma management points to the rapid increase in oil production from their wells in Galveston and Trinity Bay, just offshore form Houston, indicating that production has jumped from less than 100 BOEPD (barrels of oil equivalent per day) to over 500 BOEPD, and then states confidently that production should grow to over 1000 BOEPD by the end of the year, and 2500 BOEPD by the end of 2013, it’s not an example of executive wishful thinking. The numbers are simply based upon what has been tapped and what has been untapped.

The current 500 BOEPD is being produced by only a fraction of Duma’s available wells in the two bays. Specifically, out of the 130 wells the company has in Galveston Bay and Trinity Bay, only 27, roughly 20%, of the wells are currently active. As the other nearby wells come online, production will increase. At the same time, operational margins are expected to improve, directing more money to the bottom line.

More than beefing up Duma’s financial picture, this domestic productivity, including additional projects in Texas and other parts of the U.S., serves to finance the company’s exploration projects overseas. In particular, it currently supports Duma’s working interest in a 5.3 million acre petroleum concession in Namibia, Africa. Namibia is a small country of just over 2 million people, with a representative government that is considered one of the most stable in Africa. Duma obtained its interests through the acquisition of Namibia Exploration, now a wholly owned subsidiary.

The concession is located in the Owambo Basin in northern Namibia. The basin was formed primarily during the Proterozoic Era, and appears to contain the major elements required to produce a major petroleum system: source rock, reservoir rock, reservoir trap, and reservoir seal. Having a dependable source of income from domestic production gives Duma the opportunity to explore and develop what could become major finds.

For additional information on Duma Energy, visit the company’s website at www.DUMA.com

MusclePharm Corp. (MSLP) Combines Medical Science with Professional Field Testing

In the fast growing world of nutritional supplements, MusclePharm is distinctive in its approach to the athletic and health conscious marketplace. Calling itself the healthy lifestyle company that truly lives and breathes the healthy lifestyle, MusclePharm recruited the industry’s top doctors and nutritionists, and then provided them with a state-of-the-art athletic and testing facility featuring the best equipment available:

• Woodway Treadmills
• Keiser Machines
• Hyperbaric Machines
• Hydroworx Pool
• Omega Wave Machines
• Stem and Ultra Sound Units
• Dexa

It’s the MusclePharm Sports Science Center Research Institute in Colorado, where their team of doctors and scientists utilize an advanced 6-stage research protocol, together with extensive field testing by professional athletes from the National Football League, Mixed Martial Arts, and Major League Baseball, to formulate a full line of nutritional supplements that are 100% free of banned substances. Their clinic can perform bone scans, blood work, ultrasounds, muscle and fat evaluations, kidney and liver tests, cortisol tests, reaction-time testing, and much more. This intensive combination of science and professional field testing is unique, and gives MusclePharm an important edge. Its products are now sold around the world, including thousands of retail outlets and online stores.

All this may seem like an unnecessarily big investment, but the sports nutrition and high energy supplements market is expected by some to top $100 billion in the near future, and any chunk of that is considered worth the effort. MusclePharm is gearing itself to become the nutritional supplement line of choice for serious athletes.

For additional information, visit the company’s website at www.MusclePharm.com

Mesa Energy Holdings, Inc. (MSEH) Secures Over 3k Acres in Oklahoma Mississippian Limestone, Drilling Program Slated

Mesa Energy Holdings, the Dallas-based E&P with an extensive portfolio of domestic holdings and an emphasis on growth via acquisition/upgrading sites, with multi-well, repeatable projects in low-risk basins being the central focus, reported the successful execution of some three-year leases on approximately 1,525 net acres today in Oklahoma’s Garfield and Major Counties, as well as closing on another 1,720 net acres held by production via the Farmout Agreement with Twenty/Twenty Oil & Gas, Inc.

This is some prime territory for accessing the Mississippian Limestone, and the Farmout deal in particular is notable for including an outright purchase of three vertical wells slated to fall under purview of the company’s Oklahoma-based operating subsidiary, Mesa Midcontinent, LLC. Mesa Energy is looking at late this year or early 2013 to commence a comprehensive drilling program in the Mississippian Limestone and is in ongoing due diligence to acquire additional interests to add to this enviable 3,245 net acre position.

The collective regional position in Major and Garfield Counties is known as the Turkey Creek Project and represents another superb addition to MSEH’s already rapidly flowing production pipeline, which now totals some seven primary sites in New York and Louisiana. Now with a serious footprint in Oklahoma, MSEH is intent on maximizing productive capacity at Turkey Creek and is acquiring new acreage held by production to further shore up the company’s footing.

With targets down about 7k feet in a nice, 500-foot thick layer and the Woodford Shale (another 50-80 feet) right beneath it as a tantalizing secondary, MSEH is eager to kick off the drilling program and get at those reserves. Speaking of which, were looking at a 300k-500k bbls per well in potential reserves from the Mississippian by all accounts, including the numerous published technical reports and SEC filings from regional operators.

CEO of MSEH, Randy Griffin, underscored the proven nature of the play, with extensive drilling in the region offering a good model for drill program results. Griffin called it a great opportunity for the company to setup exactly the kind of repeatable drilling situation they have focused on in Louisiana and elsewhere, accumulating acreage and eventual throughput momentum on proven targets in an area with abundantly clear success rates.

This emerging play is right in the sweet spot for MSEH: still young enough to be snapped up at prices that will potentially translate into big downstream shareholder ROI, yet established enough that there is a surfeit of high-quality well control and other data already in the public record.

For a more detailed look at technical data on the Mississippian Limestone, or to learn more about MSEH’s operational footprint, investors should check out the latest SEC-filed 10-Q (Aug 14).

For more information, please visit the company’s website located at: www.MesaEnergy.us

The Guitammer Company (GTMM) Jump Starts Holiday Season with Shipment of New Products to Australian Distributor

The Guitammer Company, a low frequency sound technology company used by entertainment and theater audiences, today announced it has shipped new products to Pagnian Imports, its distributor for the Australasian market. Guitammer reports that product demand has a head start on the 2012 holiday season, with company sales to-date to Pagnian Imports already topping Guitammer’s full-year 2011 sales by more than 600 percent.

Guitammer says the significant hike in sales reflects continued acceptance of the company’s patented ButtKicker brand products.

Pagnian owner Hess Ghahramanian echoed the value of strong consumer sentiment.

“We are proud and also excited for the opportunity to partner with The Guitammer Company to distribute their fantastic products in Australia and New Zealand,” Ghahramanian stated in the press release. “The demand for the ButtKicker products has been huge in Australia, in fact the demand has often exceeded our stock levels so Guitammer’s increasing ability to have available inventory to meet our growing demand bodes well for sustainable sales growth in our markets.”

Increased year-to-date sales were also positively impacted by deeper working capital due to Guitammer’s successful private placement offering, which generated $1.6 million in new capital growth. Guitammer says this increase has enabled the company to secure inventory and ship products to meet demand.

“Our recently completed private placement offering has further strengthened the company’s working capital position, which has helped to drive an increase in our inventory levels commensurate with growing customer demand for ButtKicker branded products,” Mark Luden, CEO of Guitammer stated. “As a result we continue to grow revenues from our core business products as we are more favorably positioned to meet demand from key partners including Hess Ghahramanian and his team at Pagnian Imports.”

For more information visit www.guitammer.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Pumps and Dumps





By The Numbers Charts

Featured Sponsor

Daily Sponsors

The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251